Totals
- Total revenue
- $2,245,192
- Total expenses
- $1,930,908
- Contributions and grants received
- $0
- Grants paid
- $0
- Program service revenue
- $2,250,000
- Investment income
- $0
- Other revenue
- -$4,808
- Total assets, end of year
- $2,256,819
- Total liabilities, end of year
- $126,649
- Net assets or fund balances, end of year
- $2,130,170
- Program services expenses (Part IX)
- not reported
- Management and general expenses
- not reported
- Fundraising expenses
- not reported
- Program service expenses (Part III)
- $0
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
2a · Program service revenue: MEMBERSHIP DUES
total $2,250,000 · related or exempt $2,250,000
-
2f · All other program service revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
6c · Rental income or loss
real property $0 · personal property $0
-
7c · Gain or loss
securities $0 · other assets $0
-
8c · Net income from fundraising events
total $0
-
11a · Other revenue: FOREIGN CURRENCY EXCHANGE GAIN/LOSS
total -$4,808 · related or exempt -$4,808
-
11d · All other revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
11e · Other revenue, total
-$4,808
Functional expenses
Part IX, the statement of functional expenses.
-
5 · Compensation of officers, directors and key employees
total $298,844
-
7 · Other salaries and wages
total $1,156
-
11b · Fees: legal
total $190,327
-
11c · Fees: accounting
total $60,660
-
11g · Fees: other
total $0
-
13 · Office expenses
total $116,793
-
14 · Information technology
total $86,001
-
19 · Conferences, conventions and meetings
total $75,353
-
24a · Other expenses: RESEARCH & DEVELOPMENT
total $1,101,774
-
24e · All other expenses
total $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,787,403 · end of year $2,130,812
-
5 · Loans and receivables from officers and key people
end of year $0
-
6 · Loans and receivables from disqualified persons
end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $126,491 · end of year $126,007
-
10a · Land, buildings and equipment: cost or other basis
$0
-
10b · Land, buildings and equipment: accumulated depreciation
$0
-
10c · Land, buildings and equipment, net
end of year $0
-
12 · Investments: other securities
beginning of year $0
-
13 · Investments: program-related
beginning of year $0
-
15 · Other assets
beginning of year $0 · end of year $0
-
17 · Accounts payable and accrued expenses
beginning of year $98,008 · end of year $126,649
-
22 · Loans and payables to officers and key people
end of year $0
-
25 · Other liabilities
beginning of year $0 · end of year $0
-
31 · Retained earnings, endowment or other funds
beginning of year $1,815,886 · end of year $2,130,170
Mission and programs · 2024
Mission
THE PRIMARY PURPOSE OF THE CORPORATION IS TO PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. THE CORPORATION WILL PURSUE THIS PURPOSE BY PROMOTING THE DEVELOPMENT OF NEW TREATMENTS FOR EMERGING VIRAL PANDEMIC PATHOGENS THROUGH COORDINATED EARLY SCIENCE, POLICY AND ADVOCACY, STAKEHOLDER ENGAGEMENT THAT FACILITATES INFORMATION SHARING, AND ADVANCING AND CREATING EFFICIENCIES IN EARLY RESEARCH AND DEVELOPMENT AMONG ITS MEMBERS AND OTHERS IN THE ANTIVIRAL R&D ECOSYSTEM. IN THIS WAY THE CORPORATION AIMS TO SUPPORT THE 100 DAY MISSION, AN INTERNATIONAL EFFORT BY THE INTERNATIONAL PANDEMIC PREPAREDNESS SECRETARIAT (IPPS.ORG) "TO PREPARE AS MUCH AS POSSIBLE SO THAT WITHIN THE FIRST 100 DAYS A PANDEMIC THREAT IS IDENTIFIED AN INITIAL REGIMEN OF THERAPEUTICS" CAN BE MADE AVAILABLE BY RESEARCH ENTERPRISES THAT ARE SAFE, EFFECTIVE AND AFFORDABLE.
Activities or mission (Part I)
PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH ANTIVIRAL PANDEMIC PREPAREDNESS EFFORTS.
-
BEYOND COVID-19, GLOBALIZATION, URBAN EXPANSION, AND EXPLOITATION OF NATURAL HABITATS SUGGEST HUMANITY WILL FACE NEW FORMS OF RESPIRATORY AND OTHER PATHOGENS THAT HOLD THE POTENTIAL TO CAUSE PANDEMICS. ORALLY AVAILABLE SMALL-MOLECULE ANTIVIRAL DRUGS FOR RAPID MOBILIZATION AND DISTRIBUTION ARE A CRITICAL TOOL TO PROTECT SOCIETIES FROM ANOTHER VIRAL PANDEMIC. UNLIKE SOME VACCINES AND ANTIBODIES, ANTIVIRAL THERAPIES MIGHT BE LESS PRONE TO THE IMPACT OF VIRUS GENETIC EVOLUTION, MAY BE EFFECTIVE AGAINST A BROAD RANGE OF VIRUSES, AND CAN CHANGE THE COURSE OF DISEASE EVEN AFTER INFECTION. MOST SMALL MOLECULE ANTIVIRALS CAN BE PRODUCED RAPIDLY AND COST-EFFECTIVELY AT A GLOBAL SCALE IN EXISTING FACILITIES, BUT THEY REQUIRE YEARS TO DISCOVER AND DEVELOP, SO IT IS CRITICAL TO PROMOTE AND SUPPORT RESEARCH, ADVOCACY, AND SCIENTIFIC INFORMATION SHARING ACROSS THE ACADEMIC BIOTECH AND PHARMACEUTICAL INDUSTRY. IN ORDER TO CREATE EFFICIENCIES IN THE R&D ECOSYSTEM, THE CORPORATION WILL COLLABORATE WITH PARTNERS IN OTHER SECTORS AND ITS MEMBERS IN EXPLORING REDUNDANCIES AND OPPORTUNITIES TO COLLABORATE FOR THE BENEFIT OF HUMANITY SUCH AS SHARING NEW RESEARCH FINDINGS, CREATING GUIDELINES SUCH AS TARGET PRODUCT PROFILES, BENCHMARKING GLOBAL R&D EFFORTS AGAINST PATHOGENS OF PANDEMIC CONCERN AND CREATING A LISTING OF PROMISING LEAD PRODUCT CANDIDATES BY RESEARCHERS GLOBALLY. WE HOPE TO ACCELERATE THE COLLECTIVE UNDERSTANDING OF VIRAL TARGETS AND INCREASE THE LIKELIHOOD OF THE R&D ECOSYSTEM IN IDENTIFYING PROMISING LEADS. THE CORPORATION INTENDS TO FACILITATE FURTHER SCIENTIFIC INFORMATION SHARING BY DEVELOPING WHITE PAPERS ON RELEVANT TOPICS, PERFORMING A LANDSCAPE AND NEEDS ASSESSMENT ACROSS PUBLIC AND PRIVATE ANTIVIRAL RESEARCH SECTORS, AND PROVIDING KNOWLEDGE-SHARING OPPORTUNITIES THROUGH ORGANIZING MEETINGS AND SEMINARS. THE CORPORATION ALSO ORGANIZED AND PRODUCED A GLOBAL SUMMIT ON ANTIVIRAL PREPAREDNESS FOR 100 STAKEHOLDERS, PUBLISHED AND DISSEMINATED THE ANTIVIRAL SUMMIT PROCEEDINGS AND RECOMMENDATIONS, RESEARCHED, ANALYZED AND AUTHORED THE ANTIVIRAL CLINICAL DEVELOPMENT LANDSCAPE FOR PUBLICATION IN JANUARY 2024 AND DEVELOPED A TARGET COMPOUND PROFILE TO GUIDE ACADEMIC, BIOTECH, PHARMA AND GOVERNMENT DRUG DEVELOPERS IN THEIR R&D FOR ANTIVIRALS.
As filed on the 2024 return.
Listed in Part VII
-
James AndersonJAMES ANDERSON
PRESIDENT
- Total calculated
- $0
- Hours/week
- 1
-
Lydia OgdenLYDIA OGDEN
SECRETARY
- Total calculated
- $0
- Hours/week
- 1
-
Derek WallaceDEREK WALLACE
DIRECTOR (AS OF 11/2024)
- Total calculated
- $0
- Hours/week
- 1
-
Kenneth BradleyKENNETH BRADLEY
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Kumar Singh SaikatenduKUMAR SINGH SAIKATENDU
DIRECTOR (THRU 08/2024)
- Total calculated
- $0
- Hours/week
- 1
-
Margaret Chu-MoyerMARGARET CHU-MOYER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Michelle ParksMICHELLE PARKS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Sujata VaidyanathanSUJATA VAIDYANATHAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Tomas CihlarTOMAS CIHLAR
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
James BerginJAMES BERGIN
TREASURER
- Total calculated
- $0
- Hours/week
- 1
-
Nina HillNINA HILL
SECRETARIAT
- Total calculated
- $298,844
- From this org
- $298,844
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $298,844
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $298,844
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Form 990 of other organizations
- 3 · Written employment contract
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $750,000
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| Europe (Including Iceland and Greenland) | 0 | 0 | Program Services | MEMBERSHIP DUES | $750,000 |
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 8 October 2025
- IRS schema version
- 2024v5.1
- Source object
- 202502819349301900
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.